VCYT (Veracyte) Net earnings per share (EPS TTM)

VCYT (Veracyte Corp) - company brandmark

Under the leadership of Mark Staple, Veracyte, Inc. (VCYT) is implementing high-precision genomic tests, earning the absolute trust of oncologists by minimizing unnecessary surgeries. The rolling net income per share trend captures this success, where the value 1.55 records the final metric. Business growth is supported by stringent patent protections and insurance company recognition, creating an insurmountable barrier for new entrants.

VCYT veracyte.com Earnings per share for the last twelve months (07/04/2022 - 11/12/2026)

Metric breakdowns and analytics for Veracyte Inc (VCYT)

- current quotes and average value forecast:
Price Chart Veracyte, Inc.|VCYT - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization Veracyte, Inc.|VCYT - Enterprise Value
- business book valuation details:
Net Assets per Single Share Veracyte|VCYT - Company Book Value|Market Cap to Net Assets Ratio veracyte.com|VCYT - Company Assets
- debt level and financial liquidity data:
Debt to Equity Veracyte, Inc.|VCYT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Veracyte Corp|VCYT - Company Total Debt Obligations|Debt to Book Capitalization Ratio Veracyte, Inc.|VCYT - Long-Term Debt Volume|Company Current Liabilities Veracyte|Quick Ratio veracyte.com
- earnings and multiples data:
VCYT - Company Net Income|Expected Profit Veracyte, Inc.|VCYT - Company Value to Net Income|Forward P/E Multiple Veracyte|VCYT - PEG Multiple|EV/EBITDA Multiple Veracyte, Inc.|VCYT - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Veracyte|VCYT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months veracyte.com|VCYT - Net earnings per one share growth for the current year|Earnings growth forecast for next year Veracyte, Inc.
Fundamental company analysis:VCYT - Veracyte, Inc.
Mass-produced product of Veracyte Inc

Biomaterial logistics and regulatory constraints in genomic diagnostics directly impact the operational efficiency of Veracyte, Inc. (VCYT), which is reflected in the rolling year net income per share trend. This indicator measures the final earnings attributable to a single share, allowing investors to assess the business's actual ability to generate profit regardless of the total capital volume.

Competitors of Veracyte, Inc.

CAI - Earnings per share for the last twelve months|GH (guardanthealth.com) - Earnings per share for the last 12 months|CELC: Net earnings per share (EPS TTM)|GRAIL Inc (GRAL) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Myriad Genetics Corp|Earnings per share for the last twelve months CSTL|Net earnings per share for the last 12 months BNR (Burning Rock Biotech)|VNRX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Biodesix BDSX|Net earnings per share for the last four quarters Precipio Inc. (PRPO)|Check-Cap Medical - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Mainz Biomed NV MYNZ|OncoCyte Corporation (OCX) - Earnings per share for the last twelve months